Journal issues > Issue 1, February 2023 > Highlights in aggressive lymphoma

Highlights in aggressive lymphoma

SUMMARY

Many patients with an aggressive lymphoma will be cured with frontline therapy. However, relapsed patients cannot always be cured and die as a result of their disease. Fortunately, many trials in frontline and relapsed setting address the medical need of patients with a high risk of inferior survival. Especially immunotherapies have shown promising results and some of these therapies have already become standard of care, or will be in the near future. This paper provides a summary of the most interesting clinical trials in aggressive lymphoma, presented at the 2022 ASH meeting.

(BELG J HEMATOL 2023;14(1):4–9)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top